"The proof-of-phasing for phase II of the trials have been successfully undertaken and the drug will now undergo phase III of trials before being introduced in the market," Ranbaxy Laboratories Senior Vice President for New Drug Discovery Research Pradip Bhatnagar said.
The company has not decided upon any trade name for the drug research on which it started clinical trials in 2003-04, he said on the sidelines of the Public Private Partnership summit for Lifesciences Sector here.
The anti-malarial combination of arterolane and piperaquine is sought by the company to be exported to malaria affected countries of Asia, Africa and South America at an affordable cost once developed.
Earlier, Ranbaxy was working with the Geneva-based Medicines for Malaria Venture (MMV) on the drug development project as part of joint malaria drug research.
MMV walked out of the joint project in November, 2007.
